Literature DB >> 6138063

Midazolam: sleep and performance studies in middle age.

A N Nicholson, B M Stone.   

Abstract

Effects of 10, 20 and 30 mg midazolam on sleep and on performance the next day were studied in six healthy adult males aged between 47 and 53 years. The study was double-blind, placebo-controlled and included another rapidly eliminated benzodiazepine (brotizolam, 0.25 mg) as an active control. With 10 mg midazolam, sleep-onset latency was quicker, and the duration and percentage of stage 2 sleep was increased over the first 6 h. Effects of 20 and 30 mg midazolam were similar to each other. Sleep onsets were earlier, total sleep times and stage 2 sleep were increased, and the sleep efficiency indices improved. During the first 6 h there was reduced duration and percentage of drowsy (stage 1) sleep. There was no consistent evidence of delay to the first period of rapid eye movement sleep, but over the dose range the duration was reduced during the first 2 h. Digit symbol substitution did not show any residual decrement 9 h after ingestion of 10, 20 or 30 mg midazolam. Midazolam may prove to be a particularly useful hypnotic for shiftworkers whose rest periods tend to be shorter than in those who have a regular nocturnal sleep pattern.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138063      PMCID: PMC1428080          DOI: 10.1111/j.1365-2125.1983.tb02281.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Pharmacokinetic and clinical considerations in the choice of a hypnotic.

Authors:  R Amrein; M Eckert; H Haefeli; B Leishman
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

2.  Pharmacokinetics and bioavailability of midazolam in man.

Authors:  P Heizmann; M Eckert; W H Ziegler
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Hypnotic efficacy in middle age.

Authors:  A N Nicholson; B M Stone; P A Pascoe
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

  3 in total
  4 in total

1.  Efficacy and safety of midazolam and vesparax in treatment of sleep disorders.

Authors:  R Fischbach
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

2.  Midazolam and triazolam in out-patients: a double-blind comparison of hypnotic efficacy.

Authors:  J A Costa E Silva; A Acioli; C Naylor; C Jones Da Silva; I Ferreira
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Distinct effects of orexin receptor antagonist and GABAA agonist on sleep and physical/cognitive functions after forced awakening.

Authors:  Jaehoon Seol; Yuya Fujii; Insung Park; Yoko Suzuki; Fusae Kawana; Katsuhiko Yajima; Shoji Fukusumi; Tomohiro Okura; Makoto Satoh; Kumpei Tokuyama; Toshio Kokubo; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

Review 4.  Midazolam. A review of its pharmacological properties and therapeutic use.

Authors:  J W Dundee; N J Halliday; K W Harper; R N Brogden
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.